IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease: The RISE-PD Randomized Clinical Trial

IMPORTANCE: Levodopa has a short half-life and a limited window of opportunity for absorption in the proximal small intestine. IPX203 is an oral, extended-release formulation of carbidopa-levodopa developed to address these limitations. OBJECTIVE: To assess the efficacy and safety of IPX203 vs immed...

Descripción completa

Detalles Bibliográficos
Autores principales: Hauser, Robert A., Espay, Alberto J., Ellenbogen, Aaron L., Fernandez, Hubert H., Isaacson, Stuart H., LeWitt, Peter A., Ondo, William G., Pahwa, Rajesh, Schwarz, Johannes, Stocchi, Fabrizio, Zeitlin, Leonid, Banisadr, Ghazal, Fisher, Stanley, Visser, Hester, D’Souza, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425876/
https://www.ncbi.nlm.nih.gov/pubmed/37578800
http://dx.doi.org/10.1001/jamaneurol.2023.2679

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425876/
https://www.ncbi.nlm.nih.gov/pubmed/37578800
http://dx.doi.org/10.1001/jamaneurol.2023.2679

Ejemplares similares